The supplement provides clarity on terms but does not change the core proposals. Monitor the vote outcome on June 2; if approved, the ELOC and preferred financing could lead to dilution, though the $1.10 floor price offers some protection. No immediate trading catalyst.
Price Chart
Executive Summary
Jaguar Health filed a DEFA14A supplement to its definitive proxy statement, clarifying terms of Proposal 3 (equity line of credit with C/M Capital) and Proposal 4 (Series P Preferred Stock issuance). Key revisions include a $1.10 floor price for the ELOC, a requirement to use 10% of ELOC proceeds to redeem Series P Preferred Stock, and additional details on preferred stock dividend, liquidation, redemption, and triggering events. The supplement does not change the matters to be voted on at the annual meeting reconvened on June 2, 2026.
Key Financial Metrics
Key Facts
- ELOC floor price set at $1.10 per share
- 10% of ELOC proceeds to be used to redeem Series P Preferred Stock
- Series P Preferred Stock dividend rate of 8% per year, payable in cash or kind
- Preferred stock redemption cap of 19.99% of outstanding common stock unless stockholder approval obtained
- Triggering events include bankruptcy, insolvency, or shares outstanding for 3+ years, allowing forced redemption at holder's option
- Annual meeting reconvened on June 2, 2026
Financial Impact
No financial figures provided; potential dilution if proposals approved, but floor price limits downside
Risk Factors
- Potential dilution if shareholders approve issuance of shares above 19.99% threshold
- Triggering events could force issuance of additional shares
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| DEFA14A Filing (Primary) | 0001193125-26-248883 |
| Document: 0001193125-26-248883-index-headers.html | 0001193125-26-248883 |
| Document: 0001193125-26-248883-index.html | 0001193125-26-248883 |
| Document: 0001193125-26-248883.txt | 0001193125-26-248883 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 22, 2026 4d ago | S-3 | $2.04 | awaiting T+60 | — | $2.37 (−16.18%) |
Oct 8, 2026 18d ago | DEF 14A | $4.79 | awaiting T+60 | — | $2.37 (+50.52%) |
Oct 5, 2026 21d ago | 8-K | $4.73 | awaiting T+60 | — | $2.37 (+49.89%) |
Sep 28, 2026 28d ago | 8-K | $6.02 | awaiting T+60 | — | $2.37 (+60.63%) |
Sep 24, 2026 4w ago | SC 13G/A | $7.70 | awaiting T+60 | — | $2.37 (+69.22%) |
Sep 24, 2026 4w ago | 424B5 | $7.06 | awaiting T+60 | — | $2.37 (+66.43%) |
Sep 24, 2026 4w ago | 8-K | $7.06 | awaiting T+60 | — | $2.37 (+66.43%) |
Sep 21, 2026 5w ago | 8-K | $34.46 | awaiting T+60 | — | $2.37 (−93.12%) |
Sep 15, 2026 5w ago | 8-K | $0.2246 | awaiting T+60 | — | $2.37 (−955.21%) |
Sep 3, 2026 7w ago | 424B5 | $10.41 | awaiting T+60 | — | $2.37 (+77.23%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers